Want to read (8)
Human organoids: model systems for human biology and medicine
Kim J, Koo BK, Knoblich JA.
Nat Rev Mol Cell Biol · 2020
Mapping the structural core of human cerebral cortex
Hagmann P, Cammoun L, Gigandet X, Meuli R, Honey CJ, Wedeen VJ, Sporns O.
PLoS Biol · 2008
Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition
Hangauer MJ, Viswanathan VS, Ryan MJ, Bole D, Eaton JK, Matov A, Galeas J, Dhruv HD, Berens ME, Schreiber SL, McCormick F, McManus MT.
Nature · 2017
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols MC, Cortinovis DL, Leach J, Polikoff J, Barrios C, Kabbinavar F, Frontera OA, De Marinis F, Turna H, Lee JS, Ballinger M, Kowanetz M, He P, Chen DS, Sandler A, Gandara DR, OAK Study Group.
Lancet · 2017
TIMER2.0 for analysis of tumor-infiltrating immune cells
Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q, Li B, Liu XS.
Nucleic Acids Res · 2020
Super-enhancers in the control of cell identity and disease
Hnisz D, Abraham BJ, Lee TI, Lau A, Saint-André V, Sigova AA, Hoke HA, Young RA.
Cell · 2013
A framework for advancing our understanding of cancer-associated fibroblasts
Sahai E, Astsaturov I, Cukierman E, DeNardo DG, Egeblad M, Evans RM, Fearon D, Greten FR, Hingorani SR, Hunter T, Hynes RO, Jain RK, Janowitz T, Jorgensen C, Kimmelman AC, Kolonin MG, Maki RG, Powers RS, Puré E, Ramirez DC, Scherz-Shouval R, Sherman MH, Stewart S, Tlsty TD, Tuveson DA, Watt FM, Weaver V, Weeraratna AT, Werb Z.
Nat Rev Cancer · 2020
Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity
Ran FA, Hsu PD, Lin CY, Gootenberg JS, Konermann S, Trevino AE, Scott DA, Inoue A, Matoba S, Zhang Y, Zhang F.
Cell · 2013